An interesting report by Schachter et al. (1994) not only substantiated this hypothesis but in addition demonstrated an association between the E2 allele and longevityGalinsky, D., Tysoe, C., Brayne, C.E., Easton, D.F., Huppert, F.A., Dening, T.R., Paykel, Rubinsztein, D.C. (1997). Analysis of the ApoE/ApoC-I, angiotensin converting enzyme, methylenetetrahydrofolate reductase genes as candidates affecting human longevity. Haan, M.N., Shemanski, J., Jagust, W.J., Manolio, T.A., Kuller, L. (1999). The role of APOE in modulating effects of other risk factors for cognitive decline in elderly persons. Journal of the American Association. Hallman, D.M., Boerwinkle, E., Saha, N., Sandholzer, C., Menzel, H.J., Csazar, A., Utermann (1991). The apolipoprotein E polymorphism: a comparison of allele frequencies and effects in populations. American Journal of Human Genetics. Henderson, S.A., Easteal, S., Jorm A.F., Mackinnon A.J., Korten A.L., El Christensen H., Croft Jacomb P.A. (1995). Apolipoprotein E allele E and dementia and cognitive decline in a population Lancet. Jian-Gang Z., Yong-Xing M., Chuan-Fu W., Pei-Fang L., Song-Bai Z., Nui-Fan G., Guo-Yin Lin H. (1998). Apolipoprotein E and longevity among Han Chinese population. Mechanisms of Ageing and Development. Kervinen K., Savolainen M.J., Salokannel J., Hynninen A., Heikkinen J., Ehnholm C. Kesaniemi M.J. (1994). Apolipoprotein E and B polymorphism-longevity factors assessed nonagenarians. Atherosclerosis. Ligthart G.L., Corberand K.X., Fournier C., Galanaud P., Hijmans W., Kennes B. (1984). Inclusion criteria for immunogerontological studies in man: the Senieur protocol. Mechanisms of Ageing and Development. Louhija J., Miettinen H.E., Kontula K., Tikkanen M.J., Miettinen T.A., Tilvas R.S. (1995). Apolipoproteins and genetic variation of plasma apolipoproteins. Relative loss of the apolipoprotein E phenotype Centenarians. Arteriosclerosis, Thrombosis, and Vascular Biology. Alafuzoff, I., Helisalmi, S., Mannermaa, A., Soininen, H. (2000). Severity of cardiovascular disease, apolipoprotein E genotype, and brain pathology in ageing and dementia. Annals of the New York Academy of Sciences. OHara R., Yesavage J.A., Kraemer H.C., Mauricio M., Friedman L.F., Murphy G.M. (1998). APOE epsilon 4 is associated with decline on delayed recall performance in older adults. Journal of the American Geriatrics Society. Rea I.M., Master D., Woodside J.V., Young I.S., Archbold G.P.R., Linton T., Lennox Multy H. (1999). Community-living nonagenarians in Ireland have a lower plasma homocysteine but similar methylenetetrahydrofolate reductase labile genotype prevalence compared to 70-year-old subjects. Atherosclerosis. Rulu G., Cassader M., Gambino R., Alemanno N., Demichieli F., Pagano A., Veglia F. (1999). Apolipoprotein E allele frequencies in Italian populations: relation of age and lipid Aging Clinical and Experimental Research. Schachter F., Faure-Delanef, L., Guenot F., Rouger H., Froguel P., Lesueur-Ginot L., Cohen (1994). Genetic associations with human longevity at the ApoE and ACE loci. Nature Genetics. Smith J.D. (2000). Apolipoprotein E: an allele associated with many diseases. Annals of Medicine. Tunstall-Pedoe T., Kuulasmaa K., Amouyel P., Arveiler D., Rajakangas A.M., Pajek A. (1994). WHO MONICA project. Circulation. Utermann G. (1987). Apolipoprotein E polymorphism in health and disease. American Heart Journal. Xhignesse M., Lussier-Cacan S., Sing C.F., Kessling A.M., Davignon J. (1993). Influences of variants of apol